Your browser doesn't support javascript.
loading
Changes in End-of-Life Symptom Management Prescribing among Long-Term Care Residents during COVID-19.
Fremont, Deena; Roberts, Rhiannon L; Webber, Colleen; Clarke, Anna E; Milani, Christina; Isenberg, Sarina R; Bush, Shirley H; Kobewka, Daniel; Turcotte, Luke; Howard, Michelle; Boese, Kaitlyn; Arya, Amit; Robert, Benoit; Sinnarajah, Aynharan; Simon, Jessica E; Lau, Jenny; Qureshi, Danial; Downar, James; Tanuseputro, Peter.
Afiliação
  • Fremont D; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada.
  • Roberts RL; Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Webber C; Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Clarke AE; ICES uOttawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Milani C; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada.
  • Isenberg SR; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Bush SH; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada; Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Kobewka D; Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Turcotte L; Department of Health Sciences, Brock University, St Catharines, Ontario, Canada.
  • Howard M; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Boese K; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada; Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Arya A; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada; Kensington Research Institute, Toronto, Ontario, Canada.
  • Robert B; Centre of Excellence in Frailty-Informed Care, Perley Health, Ottawa, Ontario, Canada.
  • Sinnarajah A; Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Simon JE; Department of Oncology, Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Lau J; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Palliative Care, University Health Network, Toronto, Ontario, Canada.
  • Qureshi D; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada.
  • Downar J; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada; Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Tanuseputro P; Bruyère Research Institute, Bruyère Continuing Care, Ottawa, Ontario, Canada; Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: peter.tanuseputro@mail.utoronto.c
J Am Med Dir Assoc ; 25(6): 104955, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38438112
ABSTRACT

OBJECTIVE:

To examine changes in the prescribing of end-of-life symptom management medications in long-term care (LTC) homes during the COVID-19 pandemic.

DESIGN:

Retrospective cohort study using routinely collected health administrative data in Ontario, Canada. SETTING AND

PARTICIPANTS:

We included all individuals who died in LTC homes between January 1, 2017, and March 31, 2021. We separated the study into 2 periods before COVID-19 (January 1, 2017, to March 17, 2020) and during COVID-19 (March 18, 2020, to March 31, 2021).

METHODS:

For each LTC home, we measured the percentage of residents who died before and during COVID-19 who had a subcutaneous symptom management medication prescription in their last 14 days of life. We grouped LTC homes into quintiles based on their mean prescribing rates before COVID-19, and examined changes in prescribing during COVID-19 and COVID-19 outcomes across quintiles.

RESULTS:

We captured 75,438 LTC residents who died in Ontario's 626 LTC homes during the entire study period, with 19,522 (25.9%) dying during COVID-19. The mean prescribing rate during COVID-19 ranged from 46.9% to 79.4% between the lowest and highest prescribing quintiles. During COVID-19, the mean prescribing rate in the lowest prescribing quintile increased by 9.6% compared to before COVID-19. Compared to LTC homes in the highest prescribing quintile, homes in the lowest prescribing quintile experienced the highest proportion of COVID-19 outbreaks (73.4% vs 50.0%), the largest mean outbreak intensity (0.27 vs 0.09 cases/bed), the highest mean total days with a COVID-19 outbreak (72.7 vs 24.2 days), and the greatest proportion of decedents who were transferred and died outside of LTC (22.1% vs 8.6%). CONCLUSIONS AND IMPLICATIONS LTC homes in Ontario had wide variations in the prescribing rates of end-of-life symptom management medications before and during COVID-19. Homes in the lower prescribing quintiles had more COVID-19 cases per bed and days spent in an outbreak.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Assistência Terminal / Assistência de Longa Duração / SARS-CoV-2 / COVID-19 / Casas de Saúde Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Assistência Terminal / Assistência de Longa Duração / SARS-CoV-2 / COVID-19 / Casas de Saúde Limite: Aged / Aged80 / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article